ATE438859T1 - Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz - Google Patents

Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Info

Publication number
ATE438859T1
ATE438859T1 AT04764350T AT04764350T ATE438859T1 AT E438859 T1 ATE438859 T1 AT E438859T1 AT 04764350 T AT04764350 T AT 04764350T AT 04764350 T AT04764350 T AT 04764350T AT E438859 T1 ATE438859 T1 AT E438859T1
Authority
AT
Austria
Prior art keywords
insulin resistance
inhibition
kinase activity
treat insulin
kinase
Prior art date
Application number
AT04764350T
Other languages
English (en)
Inventor
Johan Auwerx
Francesca Frigerio
Stefano Fumagalli
Sara Kozma
Frederic Picard
Melanie Sticker-Jantscheff
George Thomas
Sung Um
Mitsuhiro Watanabe
Original Assignee
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung
Application granted granted Critical
Publication of ATE438859T1 publication Critical patent/ATE438859T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04764350T 2003-08-22 2004-08-20 Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz ATE438859T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49722603P 2003-08-22 2003-08-22
PCT/EP2004/009368 WO2005019829A1 (en) 2003-08-22 2004-08-20 Inhibition of s6 kinase activity for the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
ATE438859T1 true ATE438859T1 (de) 2009-08-15

Family

ID=34216100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764350T ATE438859T1 (de) 2003-08-22 2004-08-20 Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Country Status (7)

Country Link
US (1) US20070191259A1 (de)
EP (1) EP1658504B1 (de)
JP (1) JP2007503203A (de)
AT (1) ATE438859T1 (de)
DE (1) DE602004022423D1 (de)
ES (1) ES2331006T3 (de)
WO (1) WO2005019829A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
EP1799859B1 (de) * 2004-09-17 2014-07-02 Isis Pharmaceuticals, Inc. Verbesserte antisense-oligonukleotide
US7897595B2 (en) * 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2131656A4 (de) 2006-11-15 2011-12-07 Forest Lab Holdings Ltd Phthalazinderivate
CN110898225A (zh) * 2019-12-23 2020-03-24 黑龙江中医药大学 mTOR/S6K1及MAPK信号通路抑制在胰岛素抵抗改善中的应用
JP7723987B2 (ja) * 2020-04-21 2025-08-15 ユニバーシティ オブ マサチューセッツ 加齢性黄斑変性を処置するための方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US20030083284A1 (en) * 2001-08-01 2003-05-01 Isis Pharmaceuticals Inc. Antisense modulation of p70 S6 kinase expression
JP2003516760A (ja) * 1999-12-02 2003-05-20 ユニヴァーシティー オブ ダンディー プロテインキナーゼ調節
GB0224338D0 (en) * 2002-10-18 2002-11-27 Novartis Forschungsstiftung Modulation of S6 kinase activity for the treatment of obesity

Also Published As

Publication number Publication date
DE602004022423D1 (de) 2009-09-17
US20070191259A1 (en) 2007-08-16
EP1658504A1 (de) 2006-05-24
WO2005019829A1 (en) 2005-03-03
ES2331006T3 (es) 2009-12-18
JP2007503203A (ja) 2007-02-22
EP1658504B1 (de) 2009-08-05

Similar Documents

Publication Publication Date Title
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
NO20050198L (no) Mitotiske kinesininhibitorer
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
ATE513550T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE424208T1 (de) Proteinkinaseinhibitoren
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE60327793D1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
WO2006020755A3 (en) Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE412411T1 (de) Pmcol zur behandlung von prostatakrebs
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1658504

Country of ref document: EP

REN Ceased due to non-payment of the annual fee